The research published in Oral Type 2 Diabetes Clinical Pipeline Analysis details endocrinologists’ and primary care providers’ perceptions of oral therapies for type 2 diabetes currently in development. These pipeline drugs include oral insulin and Sotagliflozin. This strategy guide includes competitive assessments of each pipeline therapy compared to oral treatments already on the market, as well as highlighting HCPs’ level of familiarity and excitement for each new type 2 diabetes drug.
A new type 2 diabetes drug’s ability to generate excitement among endocrinologists and primary care providers plays a significant role in the treatment’s success or failure in a crowded market. Among oral treatments for type 2 diabetes, HCPs have more than half a dozen establish brands to choose from. Therefore, new drugs coming out of development need to differentiate themselves. And, of course, any excitement for a new oral treatment for type 2 diabetes will be tempered by its efficacy, safety and availability.
This strategy guide includes detailed insights from US endocrinologists and primary care providers about the clinical pipeline for oral type 2 diabetes treatments. The report details how healthcare providers expect each new drug will impact the oral type 2 diabetes market, how they will compete against available branded treatments and which pipeline treatments provide advantages or disadvantages due to the differentiation in their clinical attributes.
Overview of New Diabetes Medications Analysis
Oral treatments for type 2 diabetes present healthcare providers with options to treat different patients’ unique needs. New treatments in development will need to launch with different strengths and opportunities that endocrinologists and primary care providers can evaluate when prescribing a type 2 diabetes therapy. Oral Type 2 Diabetes Clinical Pipeline Analysis examines how HCPs perceive developing treatments’ strengths and weaknesses across the following six key clinical attributes:
The report also shares US healthcare providers’ familiarity and excitement about the oral type 2 diabetes clinical pipeline.
New Diabetes Medications Analyzed
- Oral insulin
Strategic Questions Answered about the Oral Type 2 Diabetes Clinical Pipeline
- Awareness: What is the level of awareness and excitement among physicians for oral type 2 diabetes pipeline therapies?
- Perceptions: How do physicians perceive new diabetes medications in terms of their efficacy, safety, dosing, tolerability, access, and support?
- Competitive Impact: Which inline type 2 diabetes brands will be most impacted in the future by pipeline therapies?
Summary of Strategic Insights about New Diabetes Medications
- There is an overall low level of familiarity with oral type 2 diabetes pipeline medications. The most familiar medication is Oral Insulin which only 21% of HCPs are familiar with.
- While only 21% of HCPs are familiar with Oral Insulin, almost thee quarters of HCPs are excited by it. This excitement is likely explained by the novel route of administration for an injectable medication.
- HCPs are evenly split between being excited (48%) vs. ambivalent (48%) towards Sotagliflozin. This suggests that HCPs are interested in Sotagliflozin but remain skeptical on how well it will perform in the market.
Benefits of Purchasing Oral Type 2 Diabetes Clinical Pipeline Analysis
- Cost-efficient insights about the oral type 2 diabetes clinical pipeline to support your strategic decisions.
- Insights drawn from in-depth interviews among US KOLs and surveys of more than 150 endocrinologists and primary care physicians
- A complimentary 30-minute workshop with you (and your team)
- Unlimited support from Vivisum’s type 2 diabetes strategist for 1-year.
Table of Contents
Executive Summary – 5
The Strategic Six – Key Insights about Oral Type 2 Diabetes Pipeline Treatments- 6
Impact Scores for Oral Type 2 Diabetes Pipeline Products- 7
Pipeline Expectations vs. Competitors – 8
Oral Type 2 Diabetes Clinical Pipeline Superlatives – 9
Pipeline Awareness & Excitement – 10
- Pipeline Treatments with the Highest Familiarity – 11
- Pipeline Treatments HCPs Have Heard of But Are Not Familiar With – 12
- Pipeline Treatments with the Least Familiarity 13
- Pipeline Treatments with the Highest Excitement -14
- Pipeline Treatments with the Highest Ambivalence – 15
Pipeline Treatment Competitive Outlook – 16
Oral Insulin (ORMD-0801) Competitive Outlook – 17
- Oral Insulin Competitive Summary – 18
- Oral Insulin Familiarity – 19
- Oral Insulin Excitement – 20
- Oral Insulin Competitors – 21
- Oral Insulin Efficacy Expectations vs. Competitors – 22
- Oral Insulin Safety Expectations vs. Competitors – 23
- Oral Insulin Dosing Expectations vs. Competitors – 24
- Oral Insulin Tolerability Expectations vs. Competitors – 25
- Oral Insulin Access Expectations vs. Competitors – 26
- Oral Insulin Support Expectations vs. Competitors – 27
Sotagliflozin Competitive Outlook – 28
- Sotagliflozin Competitive Summary – 29
- Sotagliflozin Familiarity – 30
- Sotagliflozin Excitement – 31
- Sotagliflozin Competitors – 32
- Sotagliflozin Efficacy Expectations vs. Competitors – 33
- Sotagliflozin Safety Expectations vs. Competitors – 34
- Sotagliflozin Dosing Expectations vs. Competitors – 35
- Sotagliflozin Tolerability Expectations vs. Competitors – 36
- Sotagliflozin Access Expectations vs. Competitors – 37
- Sotagliflozin Support Expectations vs. Competitors – 38
Contact – 39